Home / Deep Research / BRAF-Mutant Papillary Thyroid Cancer

BRAF-Mutant Papillary Thyroid Cancer

1. Disease Information

2026-04-05
Falcon MONDO:0005075 Model: Edison Scientific Literature 56 citations

1. Disease Information

1.1 Overview / definition

Papillary thyroid carcinoma (PTC) is the most common thyroid cancer subtype and a malignancy of thyroid follicular epithelial cells. “BRAF‑mutant PTC” refers to PTC harboring activating BRAF alterations, most commonly BRAFV600E, a driver that constitutively activates MAPK signaling. BRAFV600E is defined as c.1799T>A (p.Val600Glu). (webster2024theprevalenceand pages 2-2)

Abstract‑quotable definition (RAI‑refractory context): In radioiodine‑refractory disease, loss of differentiation features (including iodide uptake) is “correlat[ed] with the degree of mitogen‑activated protein kinase (MAPK) activation, which is higher in tumors with BRAF…mutations…Hence, inhibition of…MEK…could sensitize RAI refractivity.” (Aashiq et al., 2019; PMID not extracted by tool; DOI/URL in source) (tan2024tertpromotermutations pages 9-10)

1.2 Key identifiers and ontology mapping

Because this run’s tool outputs were optimized for literature/trials rather than ontology registries (OMIM/MeSH/ICD/MONDO direct lookups are not available as dedicated tools here), only partial identifiers can be provided: - Disease family identifiers present in Open Targets evidence: - Papillary thyroid carcinoma: Open Targets disease ID EFO_0000641 (tan2024tertpromotermutations pages 9-10) - Differentiated thyroid carcinoma: Open Targets disease ID EFO_1002017 (tan2024tertpromotermutations pages 9-10) - Gene/target: BRAF (Ensembl: ENSG00000157764) (tan2024tertpromotermutations pages 9-10)

1.3 Synonyms / alternative names

1.4 Data provenance

The information here is derived primarily from aggregated disease‑level resources (peer‑reviewed reviews, retrospective cohorts, meta‑analyses, and ClinicalTrials.gov records), rather than individual EHR records. (brumfield2025prevalenceandclinical pages 1-2, ovcaricek2024redifferentiationtherapiesin pages 6-7, NCT01534897 chunk 1)

2. Etiology

2.1 Disease causal factors

Primary causal factor (somatic driver): The dominant causal event in BRAF‑mutant PTC is a somatic activating mutation in BRAF, especially BRAFV600E, which drives high‑output MAPK/ERK signaling. (webster2024theprevalenceand pages 2-2, cortas2023tyrosinekinaseinhibitors pages 2-4)

2.2 Risk factors

Molecular risk factors for aggressive behavior / dedifferentiation - TERT promoter (TERTp) mutations are repeatedly highlighted as strong adverse prognostic markers in DTC and interact negatively with BRAFV600E. (tan2024tertpromotermutations pages 9-10)

Population/clinical risk factors for recurrence (example cohort): In a 301‑patient single‑institution cohort, recurrence was associated with large‑volume nodal disease burden and male sex, rather than BRAFV600E alone on multivariable analysis. (brumfield2025prevalenceandclinical pages 1-2)

2.3 Protective factors

Protective factors specific to BRAF‑mutant PTC were not clearly identified in the gathered evidence. However, the incidence‑trend literature argues that reductions in overdiagnosis/changes in screening and management practices can reduce observed incidence of thyroid cancer (including PTC), which can be viewed as a population‑level protective factor against overtreatment. (fwelo2024impactofamerican pages 1-2)

2.4 Gene–environment interactions

Explicit GxE interaction data were not captured in the retrieved evidence. One review notes BRAF fusions in radiation‑associated cases, indicating environmental exposure may shape mutation spectra in some settings, but quantitative interaction effects were not extractable from the provided excerpts. (voinea2024pathogenesisandmanagement pages 2-4)

3. Phenotypes (clinical presentation)

3.1 Core phenotypes and suggested HPO terms

PTC commonly presents as a thyroid nodule and may involve cervical lymphadenopathy; BRAFV600E has been associated in many meta‑analyses with adverse local features (extrathyroidal extension, nodal metastasis), though results vary by cohort and adjustment. (webster2024theprevalenceand pages 2-2, brumfield2025prevalenceandclinical pages 1-2)

Suggested phenotype mapping (HPO terms; canonical terms shown, not all were explicitly listed in the evidence excerpts): - Thyroid nodule / thyroid mass: Thyroid nodule (HP:0002890) - Cervical lymph node metastasis / lymphadenopathy: Lymphadenopathy (HP:0002716) - Extrathyroidal extension / local invasion: Invasive neoplasm (HP:0100758) (approximate mapping) - Multifocal tumors: Multifocal neoplasm (HP:0030445) (approximate mapping) - Distant metastasis (advanced cases): Metastatic neoplasm (HP:0003002)

3.2 Frequency and clinical correlations (selected recent quantitative data)

3.3 Quality of life impact

Quality‑of‑life instruments (e.g., EQ‑5D, SF‑36, PROMIS) were not reported in the evidence excerpts retrieved here; for BRAF‑mutant disease, QoL is often dominated by treatment effects (thyroidectomy, lifelong levothyroxine, potential systemic therapy toxicity in RAIR disease), but quantitative QoL data were not extractable from these sources.

4. Genetic / Molecular Information

4.1 Causal genes

4.2 Pathogenic variants

Somatic vs germline: BRAFV600E in PTC is a somatic oncogenic driver in the vast majority of cases (not presented as germline in the retrieved excerpts). (webster2024theprevalenceand pages 2-2)

4.3 Modifier/cooperating alterations

4.4 Epigenetic/chromatin mechanisms

Chromatin remodeling state can determine whether MAPK blockade can restore thyroid differentiation. Loss of SWI/SNF complex subunits in BRAF‑driven mouse models produced a repressive chromatin state and resistance to redifferentiation. (tan2024tertpromotermutations pages 9-10)

4.5 Suggested GO and Cell Ontology (CL) terms

Key pathways/processes (GO Biological Process suggestions): - MAPK cascade (GO:0000165) - ERK1/ERK2 cascade (GO:0070371) - Regulation of cell proliferation (GO:0008283) - Epithelial cell differentiation (GO:0030855) - Iodide transport (GO:0015705)

Key cell types (CL suggestions): - Thyroid follicular cell / thyrocyte (CL:0000115) - Myeloid‑derived suppressor cell (not always in CL as a single canonical term; can map to immature myeloid populations; the study explicitly focuses on MDSCs) (tan2024tertpromotermutations pages 9-10)

5. Environmental Information

No specific toxins, lifestyle factors, or infectious agents were supported by the retrieved evidence snippets as causal contributors specifically to BRAF‑mutant PTC. In the incidence‑trend literature, imaging and screening practices are emphasized as drivers of apparent incidence, rather than an identified infectious etiology. (fwelo2024impactofamerican pages 1-2)

6. Mechanism / Pathophysiology

6.1 Causal chain (high‑level)

  1. Somatic BRAFV600E activates the MAPK/ERK pathway with high signaling output. (webster2024theprevalenceand pages 2-2, cortas2023tyrosinekinaseinhibitors pages 2-4)
  2. High MAPK output drives dedifferentiation (downregulation of thyroid lineage transcriptional programs) and disrupts the iodide‑handling machinery, including NIS/SLC5A5 expression and/or membrane targeting. (voinea2024pathogenesisandmanagement pages 2-4, chen2024systemictreatmentsfor pages 1-2)
  3. Reduced NIS function causes loss of radioiodine avidity and contributes to radioiodine‑refractory (RAIR) disease, which has markedly worse outcomes. (cortas2023tyrosinekinaseinhibitors pages 1-2, chen2024systemictreatmentsfor pages 1-2)
  4. Co‑mutations (e.g., TERT promoter) accelerate progression/dedifferentiation, increasing RAIR likelihood and worsening prognosis. (tan2024tertpromotermutations pages 9-10)

Abstract‑quotable mechanistic framing (RAIR‑DTC): “alterations…initiating tumour cell dedifferentiation events, accompanied by reduced or virtually absent expression of the sodium/iodine symporter (NIS)…[leading to] iodine‑refractory differentiated thyroid cancer (RAIR‑DTC)” (Zhao et al., Frontiers in Endocrinology 2024; URL: https://doi.org/10.3389/fendo.2023.1320044). (tan2024tertpromotermutations pages 9-10)

6.2 Immune microenvironment mechanism (expert mechanistic insight)

BRAFV600E can promote immune suppression via a TBX3–CXCR2 ligand axis that recruits myeloid‑derived suppressor cells (MDSCs); experimental inhibition of CXCR2 or repression of MDSCs improved the effect of MAPK inhibitor therapy in advanced thyroid cancer models. (Zhang et al., Nature Communications 2022; URL: https://doi.org/10.1038/s41467-022-29000-5). (tan2024tertpromotermutations pages 9-10)

7. Anatomical Structures Affected

7.1 Organ/tissue

7.2 Subcellular (GO Cellular Component suggestions)

8. Temporal Development

8.1 Onset

Typically adult onset (many cases diagnosed in middle age), with notable incidence in young adults; PTC is also common in pediatric/adolescent thyroid cancers but BRAFV600E is less frequent in children than adults. (branigan2023developmentofnovel pages 1-2, cortas2023tyrosinekinaseinhibitors pages 2-4)

8.2 Progression

Most DTC/PTC is indolent, but a subset progresses to metastatic and RAIR disease. Reviews cited in this run indicate that RAIR disease comprises 5–15% of DTCs and ~50% of metastatic DTCs, reflecting progression/dedifferentiation in advanced settings. (chen2024systemictreatmentsfor pages 1-2)

9. Inheritance and Population

9.1 Epidemiology and trends

SEER‑based U.S. incidence trends (2000–2020) and guideline inflection points: A joinpoint analysis of SEER data found thyroid cancer incidence increased rapidly from 2000–2009 (AAPC 5.8%), increased modestly 2010–2015 (AAPC 1.1%), then decreased significantly 2016–2020 (AAPC −4.8%), with inflection points around 2009 and 2015 aligned to ATA management revisions. (Fwelo et al., Journal of Clinical Medicine, Dec 2024; URL: https://doi.org/10.3390/jcm14010028). (fwelo2024impactofamerican pages 1-2)

Histology‑specific trends: In the same study’s stratified results, papillary thyroid carcinoma showed the largest increase over 2000–2020 (overall APC 3.3) while follicular thyroid carcinoma declined modestly. (fwelo2024impactofamerican pages 7-8)

9.2 BRAF mutation prevalence in PTC

A 2025 single‑institution cohort reported 78.7% BRAFV600E prevalence, with strong subtype enrichment (classic PTC 88%; tall cell 100%). (brumfield2025prevalenceandclinical pages 1-2)

9.3 Inheritance

BRAFV600E in PTC is primarily somatic; Mendelian inheritance is not applicable for the disease entity as defined here. (webster2024theprevalenceand pages 2-2)

10. Diagnostics

10.1 Pathology and molecular testing

Actionable biomarker testing (expert consensus): A 2024 expert panel consensus statement emphasizes that identification of actionable biomarkers via germline and somatic testing is now integral to thyroid cancer management, and notes that RET and BRAF testing are well established. (Mete et al., Endocrine Pathology, Nov 2024; URL: https://doi.org/10.1007/s12022-024-09836-x). (tan2024tertpromotermutations pages 9-10)

BRAFV600E detection: The Brumfield cohort notes VE1 immunohistochemistry is used clinically and described as highly sensitive/specific in that context. (brumfield2025prevalenceandclinical pages 1-2)

10.2 Imaging / RAIR evaluation

RAIR‑DTC is characterized by absent or lost radioiodine uptake; reviews describe a diagnostic shift to alternative imaging (e.g., FDG PET/CT in RAIR contexts) and exploration of additional tracers, though specific performance statistics were not extractable from the cited excerpts. (tan2024tertpromotermutations pages 9-10)

11. Outcome / Prognosis

11.1 Prognostic biomarkers and statistics

TERT promoter as major adverse prognostic marker and BRAFV600E synergy: - In a 243‑patient DTC NGS cohort, among those with TERTp mutations, 80% (20/25) had RAIR‑DTC; RAIR‑DTC was 6.3% (9/143) in BRAFV600E‑only vs 82.4% (14/17) in BRAFV600E+TERTp. (Tan et al., Scientific Reports, Oct 2024; URL: https://doi.org/10.1038/s41598-024-75087-9). (tan2024tertpromotermutations pages 9-10)

Stage‑system integration (expert analysis): BRAFV600E alone did not correlate strongly with ATA/TNM staging and did not significantly predict persistent disease in one 296‑patient study, whereas TERTp (alone or with BRAFV600E) correlated with higher ATA/TNM stages and predicted persistent disease. (Mukhtar et al., Frontiers in Endocrinology, Oct 2023; URL: https://doi.org/10.3389/fendo.2023.1270796). (tan2024tertpromotermutations pages 9-10)

RAIR prognosis: Reviews in this run summarize markedly poor outcomes once RAIR develops (e.g., 5‑year OS reported as ~10% in one review excerpt; additional reviews report very poor long‑term survival). (cortas2023tyrosinekinaseinhibitors pages 1-2, tan2024tertpromotermutations pages 9-10)

12. Treatment

12.1 Standard real‑world management in differentiated thyroid cancer

  • Surgery (thyroidectomy with risk‑adapted lymph node management)
  • Radioiodine (I‑131) for appropriately selected cases
  • TSH suppression with levothyroxine as standard adjunctive management These are referenced as the standard backbone in RAIR‑DTC reviews as the pre‑RAIR state; specific surgical outcome statistics were not extractable from the evidence snippets in this run. (chen2024systemictreatmentsfor pages 1-2)

MAXO suggestions: - Thyroidectomy (MAXO term suggestion: thyroidectomy) - Radioiodine therapy (MAXO suggestion: radioiodine therapy) - Thyroid hormone suppression therapy (MAXO suggestion: hormone therapy)

12.2 Systemic therapy for RAIR‑DTC (standards and targeted options)

Multiple contemporary reviews agree that for RAIR differentiated thyroid cancer: - Lenvatinib and sorafenib are standard first‑line multitargeted TKIs. - Cabozantinib is a standard second‑line option after progression on prior TKI therapy. (Chen et al., Frontiers in Endocrinology 2024; URL: https://doi.org/10.3389/fendo.2024.1346476) (chen2024systemictreatmentsfor pages 1-2)

A 2023 review similarly states: “Currently, Lenvatinib and Sorafenib…represent the standard first‑line systemic treatment options…while Cabozantinib is the standard second‑line treatment option.” (Cortas & Charalambous, Life 2023; URL: https://doi.org/10.3390/life14010022) (cortas2023tyrosinekinaseinhibitors pages 1-2)

12.3 BRAF‑directed therapy and outcomes in BRAF‑mutant RAIR‑DTC

Anti‑proliferative targeted therapy (not redifferentiation‑specific): - Vemurafenib in BRAF‑mutant RAIR‑DTC showed objective responses in a phase II experience summarized in a 2023 review: ORR 38.5% (treatment‑naïve) and 27.3% (previous VEGFR inhibitor), with toxicity including grade 3–4 AEs (65%) and secondary skin squamous cell carcinoma (27%). (cortas2023tyrosinekinaseinhibitors pages 10-12) - A randomized phase II comparison of dabrafenib vs dabrafenib+trametinib reported ORRs in the ~30–48% range depending on response criteria (modified‑RECIST vs RECIST 1.1). (cortas2023tyrosinekinaseinhibitors pages 10-12)

12.4 Redifferentiation therapy (MAPK pathway inhibition to restore RAI uptake)

Key concept: Short‑course MAPK pathway inhibition (BRAF±MEK inhibition) can restore NIS function/iodide uptake in some BRAFV600E‑mutant RAIR tumors, enabling “salvage” I‑131 therapy. (cortas2023tyrosinekinaseinhibitors pages 14-15, ovcaricek2024redifferentiationtherapiesin pages 6-7)

Recent/redifferentiation outcomes highlighted in 2024 review: - In a phase II BRAF‑mutant cohort (MERAIODE approach with dabrafenib + trametinib), post‑therapy uptake occurred in 20/21 evaluable patients; at 6 months: PR 38% (8/21), SD 52% (11/21), PD 10% (2/21); PFS 82% at 1 year and 68% at 2 years. (Ovčariček et al., J Clin Med, Nov 2024; URL: https://doi.org/10.3390/jcm13237021) (ovcaricek2024redifferentiationtherapiesin pages 6-7)

Real‑world implementation caution: A Mayo Clinic retrospective series of 33 RAIR‑DTC patients receiving genotype‑guided inhibitors reported restored RAI uptake in 57.6% overall, but only 38.9% (7/18) of BRAF‑mutant tumors redifferentiated versus 100% (11/11) RAS‑mutant tumors, suggesting BRAF‑mutant follicular‑lineage context and/or deeper dedifferentiation may limit redifferentiation success. (Toro‑Tobon et al., Thyroid, Jan 2024; URL: https://doi.org/10.1089/thy.2023.0456) (jesus2023addonradioiodineduring pages 1-3)

12.5 Ongoing and completed clinical trials (ClinicalTrials.gov)

Selected BRAF‑mutant PTC/DTC trials retrieved in this run: - NCT01534897 (completed; results posted 2017‑03‑15): Dabrafenib (GSK2118436) redifferentiation strategy in radioiodine‑refractory BRAF V600E PTC; primary outcome = number of patients with increased RAI uptake after ~25 days of dabrafenib; designed to deliver therapeutic I‑131 if uptake restored. (ClinicalTrials.gov; https://clinicaltrials.gov/study/NCT01534897) (NCT01534897 chunk 1) - NCT01286753 (completed): Vemurafenib in metastatic/unresectable BRAF V600 mutation PTC; clinical publication cited in the record (Brose et al., Lancet Oncology 2016). (https://clinicaltrials.gov/study/NCT01286753) (NCT01286753 chunk 2) - NCT04061980 (active/pending in review excerpt): Encorafenib + binimetinib ± nivolumab in metastatic RAIR BRAF V600 mutant thyroid cancer; phase 2 with ORR primary endpoint. (https://clinicaltrials.gov/study/NCT04061980) (cortas2023tyrosinekinaseinhibitors pages 19-20) - NCT06440850 (recruiting; start 2024‑07‑15): Vemurafenib + cobimetinib as a redifferentiation strategy before initial RAI in high‑risk BRAFV600E‑mutant DTC; primary outcome uses ATA response categories. (https://clinicaltrials.gov/study/NCT06440850) (NCT06440850 chunk 1)

13. Prevention

No disease‑specific primary prevention strategies exist for sporadic BRAFV600E‑mutant PTC. However, overdiagnosis mitigation (risk‑adapted ultrasound/FNA, refined biopsy criteria, and guideline‑driven management) is supported as a public‑health strategy to reduce unnecessary diagnosis/treatment burden. SEER trend inflection points aligned with ATA revisions support this interpretation. (fwelo2024impactofamerican pages 1-2, fwelo2024impactofamerican pages 2-4)

14. Other Species / Natural Disease

Natural companion‑animal disease analogs were not retrieved in the evidence excerpts. This report focuses on mechanistic translation using experimental models (see below).

15. Model Organisms / Model Systems

15.1 Mouse models

Authoritative review evidence indicates genetically engineered mouse models (GEMMs) with thyroid‑specific BRAFV600E expression closely phenocopy human PTC histology; in mice, Braf‑driven initiation depends on TSH receptor signaling, and MAPK inhibition can restore differentiation and radioiodine avidity. (Fagin et al., Nat Rev Cancer 2023; URL: https://doi.org/10.1038/s41568-023-00598-y) (fagin2023pathogenesisofcancers pages 24-25)

15.2 Murine BRAFV600E PTC cell lines from GEMMs (2023 development)

A 2023 study generated six novel murine BRAFV600E‑driven PTC cell lines derived from a BrafV600E+/−/Pten+/−/TPO‑Cre model; the lines span varied developmental stages/sexes and show differing differentiation and invasive potential, enabling preclinical therapeutic evaluation and transplantation into immunocompetent hosts. (Branigan et al., Cancers, Jan 2023; URL: https://doi.org/10.3390/cancers15030879) (branigan2023developmentofnovel pages 1-2)

15.3 Organoids

A 2024 Oncogene paper created thyroid organoids with inducible murine BrafV637E (human‑equivalent of BRAF V600E), reporting that Braf activation triggers MAPK activation and dedifferentiation, and that combining MAPK and PI3K inhibitors reversed dedifferentiation and restored follicle organization/function in vitro. (Lasolle et al., Oncogene, Nov 2024; URL: https://doi.org/10.1038/s41388-023-02889-y). (tan2024tertpromotermutations pages 9-10)

15.4 Engineered embryonic stem cell thyroid cancer systems

A Nature Communications 2023 study engineered thyroid progenitor cells with BRAF V600E (or NRAS Q61R) using CRISPR‑Cas9 to generate thyroid cancer histotypes in vitro/in vivo; BRAF V600E in thyroid progenitors generated papillary thyroid carcinoma‑like tumors, supporting a progenitor‑state susceptibility concept. (Veschi et al., Nat Commun, Mar 2023; URL: https://doi.org/10.1038/s41467-023-36922-1). (tan2024tertpromotermutations pages 9-10)

Summary evidence map

Table (click to expand)
Feature Evidence/Mechanism Clinical implication Key quantitative data (if available) Key sources (include year, journal, DOI/URL)
BRAFV600E definition Canonical activating BRAF missense hotspot caused by c.1799T>A (p.Val600Glu); constitutively activates RAF kinase signaling and is the predominant BRAF alteration in PTC. Defines a major molecular subtype of PTC; supports molecular diagnosis, prognostic contextualization, and eligibility for targeted/redifferentiation strategies. BRAF mutations occur in ~45% of PTC overall in one 2024 meta-analysis abstract; broader literature range for PTC 29%–83%. Webster 2024, Head & Neck, doi:10.1002/hed.27950, https://doi.org/10.1002/hed.27950 (webster2024theprevalenceand pages 2-2)
MAPK pathway activation BRAFV600E drives constitutive MAPK/ERK signaling (RAS/RAF/MEK/ERK). TCGA-style molecular classification recognizes BRAF-like tumors as high MAPK-output tumors; BRAF is a principal truncal driver in PTC. Promotes tumor initiation/progression, dedifferentiation, and aggressiveness; provides rationale for BRAF/MEK inhibitor therapy and short-course redifferentiation before RAI. BRAF alterations described as the single most common driver in PTC; one review cites 58.5% prevalence of BRAF alterations in PTC. Cortas 2023, Life, doi:10.3390/life14010022, https://doi.org/10.3390/life14010022 (cortas2023tyrosinekinaseinhibitors pages 2-4); Voinea 2024, review excerpt (voinea2024pathogenesisandmanagement pages 2-4)
NIS downregulation and RAI refractoriness High MAPK output from BRAFV600E suppresses thyroid-differentiation genes and impairs NIS/SLC5A5 expression and/or membrane localization, causing loss of iodine uptake. Aberrant methylation and additional pathway changes can reinforce this state. Major mechanistic basis for radioiodine-refractory (RAIR) disease; supports genotype-guided redifferentiation with MAPK inhibition. Reviews cite RAIR disease in 5%–15% of DTCs and ~50% of metastatic DTCs; another review notes ~60% of metastatic patients develop RAIR disease over time. Voinea 2024, review excerpt (voinea2024pathogenesisandmanagement pages 2-4); Chen 2024, Front Endocrinol, doi:10.3389/fendo.2024.1346476, https://doi.org/10.3389/fendo.2024.1346476 (chen2024systemictreatmentsfor pages 1-2); de Jesus 2023, Endocrine, doi:10.1007/s12020-023-03388-6, https://doi.org/10.1007/s12020-023-03388-6 (jesus2023addonradioiodineduring pages 1-3)
TERT promoter co-mutation synergy with BRAFV600E TERT promoter mutation is a strong progression marker; when combined with BRAFV600E it marks a highly aggressive molecular subset with faster dedifferentiation/RAIR conversion and poorer outcomes. Helps identify patients at higher risk for persistent disease, distant spread, earlier RAIR transition, and worse prognosis; supports broader molecular profiling beyond BRAF alone. In Tan 2024, among patients with TERTp mutations, 80% (20/25) had RAIR-DTC; RAIR prevalence was 6.3% (9/143) with BRAFV600E alone versus 82.4% (14/17) with BRAFV600E + TERTp. Mukhtar 2023: TERTp present in 37.2% with persistent disease vs 15.4% without evidence of disease; BRAFV600E alone did not predict persistent disease. Tan 2024, Sci Rep, doi:10.1038/s41598-024-75087-9, https://doi.org/10.1038/s41598-024-75087-9 (tan2024tertpromotermutations pages 9-10); Mukhtar 2023, Front Endocrinol, doi:10.3389/fendo.2023.1270796, https://doi.org/10.3389/fendo.2023.1270796 (tan2024tertpromotermutations pages 9-10)
Histologic subtype enrichment BRAFV600E is enriched in classic and tall-cell PTC versus follicular-patterned tumors. Subtype enrichment partly explains why BRAFV600E tracks with aggressive morphology but may not independently predict recurrence once major clinicopathologic factors are accounted for. Brumfield 2025: 78.7% overall BRAF p.V600E prevalence (301 cases); 88% of classic PTC, 38% of PTC with extensive follicular growth, 100% of tall-cell subtype were BRAF-positive. Brumfield 2025, Endocrine Pathology, doi:10.1007/s12022-025-09859-y, https://doi.org/10.1007/s12022-025-09859-y (brumfield2025prevalenceandclinical pages 1-2)
Clinicopathologic aggressiveness associations Across meta-analytic/review literature, BRAFV600E is linked with adverse features such as extrathyroidal extension, advanced stage, lymph-node metastasis, and recurrence; however, effect sizes vary by cohort and covariate adjustment. BRAF status is best interpreted together with stage, histology, nodal burden, and co-mutations rather than as a stand-alone prognostic biomarker. Webster 2024 review/meta-analysis excerpt states association with extrathyroidal extension, advanced stage, lymph-node metastasis, and recurrence; Brumfield 2025 found no independent association with recurrence in multivariable analysis (HR 0.71, 95% CI 0.31–1.65; p=0.4) and no association with tumor size (p=0.696) or nodal burden (p=0.962). Webster 2024, Head & Neck, doi:10.1002/hed.27950, https://doi.org/10.1002/hed.27950 (webster2024theprevalenceand pages 2-2); Brumfield 2025, Endocrine Pathology, doi:10.1007/s12022-025-09859-y, https://doi.org/10.1007/s12022-025-09859-y (brumfield2025prevalenceandclinical pages 1-2)
Allele frequency / mutation burden within BRAF-positive tumors Higher mutant allele fraction may reflect clonality/tumor burden and correlate with aggressive phenotype. May improve risk stratification among BRAF-positive PTCs beyond binary mutation status. Abdulhaleem 2023: aggressive-feature nodules had mean BRAF V600E AF 25.8% vs 10.25% in non-aggressive group (p=0.020); positive sentinel LN 29% vs negative sentinel LN 17.8% (p=0.021). Abdulhaleem 2023, Cancers, doi:10.3390/cancers16010113, https://doi.org/10.3390/cancers16010113 (derived from retrieved paper context summarized earlier; no context id available, so supporting citation omitted from parenthetical)
RAIR prognosis Once dedifferentiation leads to RAIR-DTC, prognosis worsens markedly compared with conventional DTC. Justifies earlier molecular testing, referral, and consideration of systemic therapy/redifferentiation protocols. Reviews cited 5-year OS ~10% after RAIR develops; another review states mean life expectancy 3–5 years for RAIR-TC and a 10-year survival <10% in advanced RAIR-DTC. Cortas 2023, Life, doi:10.3390/life14010022, https://doi.org/10.3390/life14010022 (cortas2023tyrosinekinaseinhibitors pages 1-2); Yu 2023, Asia Pac J Clin Oncol, doi:10.1111/ajco.13836, https://doi.org/10.1111/ajco.13836 (yu2023molecularbasisand pages 5-6); Zhao 2024, Front Endocrinol, doi:10.3389/fendo.2023.1320044, https://doi.org/10.3389/fendo.2023.1320044
Redifferentiation with BRAF/MEK inhibition Short-course inhibition of BRAFV600E/MAPK can restore NIS expression/iodine uptake in some RAIR tumors, enabling salvage RAI. Important real-world and trial strategy for BRAFV600E-mutant RAIR PTC/DTC; response is incomplete and likely modified by lineage state and co-alterations. Dabrafenib restored RAI uptake in 60% (6/10) BRAF V600E cases; after RAI, 2 PR + 4 SD at 6 months. MERAIODE BRAF-mutant cohort: uptake in 20/21 evaluable patients; 6-month PR 38% (8/21), SD 52% (11/21), PD 10% (2/21); 1-year PFS 82%, 2-year PFS 68%. Mayo retrospective series: only 38.9% (7/18) of BRAF-mutant tumors redifferentiated versus 100% (11/11) RAS-mutant tumors. Cortas 2023, Life, doi:10.3390/life14010022, https://doi.org/10.3390/life14010022 (cortas2023tyrosinekinaseinhibitors pages 14-15); Ovčariček 2024, J Clin Med, doi:10.3390/jcm13237021, https://doi.org/10.3390/jcm13237021 (ovcaricek2024redifferentiationtherapiesin pages 6-7); Toro-Tobon 2024, Thyroid, doi:10.1089/thy.2023.0456, https://doi.org/10.1089/thy.2023.0456 (jesus2023addonradioiodineduring pages 1-3)
Immune suppression axis: TBX3–CXCR2 ligands–MDSCs BRAFV600E can foster an immunosuppressive microenvironment through TBX3 reactivation and CXCR2-ligand induction, recruiting myeloid-derived suppressor cells (MDSCs); CXCR2/MDSC targeting improves MAPKi response in models. Suggests that resistance is not purely cell-intrinsic; supports combined targeted plus immune-microenvironment strategies. Nature Communications study identified a BRAFV600E–TBX3–CXCLs–MDSCs axis and showed CXCR2 inhibition/MDSC repression improved MAPKi efficacy in advanced thyroid cancer models. Zhang 2022, Nat Commun, doi:10.1038/s41467-022-29000-5, https://doi.org/10.1038/s41467-022-29000-5 (tan2024tertpromotermutations pages 9-10)
Epigenetic/chromatin resistance: SWI/SNF loss In BRAF-driven thyroid cancer, loss of SWI/SNF subunits creates a repressive chromatin state with persistent loss of thyroid-lineage transcription/differentiation programs that is not reversed by MAPK blockade. Mechanistic explanation for failure of redifferentiation despite BRAF/MEK inhibition; argues for multi-omics profiling in refractory disease. Saqcena 2021 showed BrafV600E-mutant mouse PTCs have reduced lineage TF accessibility and radioiodine incorporation that is rescued by MAPK inhibition, but SWI/SNF loss rendered tumors insensitive to redifferentiation. Saqcena 2021, Cancer Discovery, doi:10.1158/2159-8290.CD-20-0735, https://doi.org/10.1158/2159-8290.CD-20-0735 (tan2024tertpromotermutations pages 9-10)
Actionable biomarker testing context Recent consensus guidance recommends systematic somatic biomarker assessment in thyroid cancer because actionable alterations (BRAF, RET, NTRK, others) now guide therapy. In BRAF-mutant PTC, molecular testing is clinically useful not only diagnostically but also for trial access, targeted therapy selection, and redifferentiation planning. 2024 consensus statement notes RET and BRAF testing are well established in thyroid cancer care; modern algorithms emphasize multidisciplinary integration. Mete 2024, Endocrine Pathology, doi:10.1007/s12022-024-09836-x, https://doi.org/10.1007/s12022-024-09836-x (tan2024tertpromotermutations pages 9-10)

Table: This table summarizes the main molecular mechanisms and clinically relevant associations in BRAF-mutant papillary thyroid carcinoma, including dedifferentiation, radioiodine refractoriness, prognostic modifiers, and resistance biology. It is useful as a compact evidence map for knowledge-base curation and clinical interpretation.

Notes on evidence gaps

  • Direct ontology identifiers (MeSH tree number, ICD‑10/ICD‑11 codes, Orphanet/OMIM entries) and disease‑specific MONDO IDs were not retrievable with the available tools in this run; the closest structured disease IDs obtained were Open Targets EFO IDs for papillary thyroid carcinoma and differentiated thyroid carcinoma. (tan2024tertpromotermutations pages 9-10)
  • Detailed symptom frequencies, formal diagnostic criteria, and QoL metrics were not present in the excerpts captured; these typically require guideline PDFs or dedicated clinical cohorts focused on presentation/QoL.

References

  1. (webster2024theprevalenceand pages 2-2): Alyssa Webster, Rami M. Elshazli, Dylan Pinion, Robert D. E. Clark, Grace Kelly, Peter P. Issa, Mohammad H. Hussein, Manal S. Fawzy, Eman A. Toraih, and Emad Kandil. The prevalence and prognostic implications of brafk601e mutations in thyroid neoplasms: a systematic review and meta‐analysis. Head & Neck, 46:3133-3145, Oct 2024. URL: https://doi.org/10.1002/hed.27950, doi:10.1002/hed.27950. This article has 2 citations.

  2. (tan2024tertpromotermutations pages 9-10): Gongxun Tan, Bingquan Jin, Xiaoqin Qian, Yuguo Wang, Guoliang Zhang, Enock Adjei Agyekum, Feng Wang, Liang Shi, Yue Zhang, Zhenwei Mao, Chunhe Shi, Ying Xu, Xiuying Li, Lele Zhang, and Shaohua Li. Tert promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-75087-9, doi:10.1038/s41598-024-75087-9. This article has 13 citations and is from a peer-reviewed journal.

  3. (abdelmoula2024reviewhistopathologicalmolecularclassifications pages 5-5): NB Abdelmoula and B Abdelmoula. Review histopathological-molecular classifications of papillary thyroid cancers: challenges in genetic practice settings. Unknown journal, 2024.

  4. (brumfield2025prevalenceandclinical pages 1-2): Alexandria Brumfield, Sara Abou Azar, Rachel Nordgren, Ronald N. Cohen, David Sarne, Xavier M. Keutgen, Megan Applewhite, Peter Angelos, and Nicole A. Cipriani. Prevalence and clinical impact of braf p.v600e mutation in papillary thyroid carcinoma. Endocrine Pathology, Apr 2025. URL: https://doi.org/10.1007/s12022-025-09859-y, doi:10.1007/s12022-025-09859-y. This article has 10 citations and is from a peer-reviewed journal.

  5. (ovcaricek2024redifferentiationtherapiesin pages 6-7): Petra Petranović Ovčariček, Murat Tuncel, Atena Aghaee, Alfredo Campennì, and Luca Giovanella. Redifferentiation therapies in thyroid oncology: molecular and clinical aspects. Journal of Clinical Medicine, 13:7021, Nov 2024. URL: https://doi.org/10.3390/jcm13237021, doi:10.3390/jcm13237021. This article has 8 citations.

  6. (NCT01534897 chunk 1): Lori J. Wirth, MD. Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436. Massachusetts General Hospital. 2012. ClinicalTrials.gov Identifier: NCT01534897

  7. (cortas2023tyrosinekinaseinhibitors pages 2-4): Christos Cortas and Haris Charalambous. Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer. Life, 14:22, Dec 2023. URL: https://doi.org/10.3390/life14010022, doi:10.3390/life14010022. This article has 13 citations.

  8. (fwelo2024impactofamerican pages 1-2): Pierre Fwelo, Natalia I. Heredia, Ruosha Li, Ayrton Bangolo, Vignesh K. Nagesh, Simcha Weissman, and Xianglin L. Du. Impact of american thyroid association’s revised cancer management guidelines on thyroid cancer incidence trends: a retrospective cohort study, 2000–2020. Journal of Clinical Medicine, 14:28, Dec 2024. URL: https://doi.org/10.3390/jcm14010028, doi:10.3390/jcm14010028. This article has 2 citations.

  9. (voinea2024pathogenesisandmanagement pages 2-4): IA Voinea, E Petrova, N Dumitru, and A Cocoloș. Pathogenesis and management strategies in radioiodine-refractory differentiated thyroid cancer: from molecular mechanisms toward therapeutic approaches …. Unknown journal, 2024.

  10. (chen2024systemictreatmentsfor pages 1-2): Piaohong Chen, Yu Yao, Huiwen Tan, and Jianwei Li. Systemic treatments for radioiodine-refractory thyroid cancers. Frontiers in Endocrinology, Oct 2024. URL: https://doi.org/10.3389/fendo.2024.1346476, doi:10.3389/fendo.2024.1346476. This article has 15 citations.

  11. (cortas2023tyrosinekinaseinhibitors pages 1-2): Christos Cortas and Haris Charalambous. Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer. Life, 14:22, Dec 2023. URL: https://doi.org/10.3390/life14010022, doi:10.3390/life14010022. This article has 13 citations.

  12. (branigan2023developmentofnovel pages 1-2): Grace Purvis Branigan, Victoria Casado-Medrano, Alison B. O’Neill, Julio C. Ricarte-Filho, Nicole Massoll, Madeleine Salwen, Zachary Spangler, Michele Scheerer, Edward K. Williamson, Andrew J. Bauer, and Aime T. Franco. Development of novel murine brafv600e-driven papillary thyroid cancer cell lines for modeling of disease progression and preclinical evaluation of therapeutics. Cancers, 15:879, Jan 2023. URL: https://doi.org/10.3390/cancers15030879, doi:10.3390/cancers15030879. This article has 3 citations.

  13. (fwelo2024impactofamerican pages 7-8): Pierre Fwelo, Natalia I. Heredia, Ruosha Li, Ayrton Bangolo, Vignesh K. Nagesh, Simcha Weissman, and Xianglin L. Du. Impact of american thyroid association’s revised cancer management guidelines on thyroid cancer incidence trends: a retrospective cohort study, 2000–2020. Journal of Clinical Medicine, 14:28, Dec 2024. URL: https://doi.org/10.3390/jcm14010028, doi:10.3390/jcm14010028. This article has 2 citations.

  14. (cortas2023tyrosinekinaseinhibitors pages 10-12): Christos Cortas and Haris Charalambous. Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer. Life, 14:22, Dec 2023. URL: https://doi.org/10.3390/life14010022, doi:10.3390/life14010022. This article has 13 citations.

  15. (cortas2023tyrosinekinaseinhibitors pages 14-15): Christos Cortas and Haris Charalambous. Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer. Life, 14:22, Dec 2023. URL: https://doi.org/10.3390/life14010022, doi:10.3390/life14010022. This article has 13 citations.

  16. (jesus2023addonradioiodineduring pages 1-3): Filipe Miguel Montes de Jesus, Vittoria Espeli, Gaetano Paone, and Luca Giovanella. Add-on radioiodine during long-term braf/mek inhibition in patients with rai-refractory thyroid cancers: a reasonable option? Endocrine, 81:450-454, May 2023. URL: https://doi.org/10.1007/s12020-023-03388-6, doi:10.1007/s12020-023-03388-6. This article has 6 citations and is from a peer-reviewed journal.

  17. (NCT01286753 chunk 2): A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation. Hoffmann-La Roche. 2011. ClinicalTrials.gov Identifier: NCT01286753

  18. (cortas2023tyrosinekinaseinhibitors pages 19-20): Christos Cortas and Haris Charalambous. Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer. Life, 14:22, Dec 2023. URL: https://doi.org/10.3390/life14010022, doi:10.3390/life14010022. This article has 13 citations.

  19. (NCT06440850 chunk 1): Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation. City of Hope Medical Center. 2024. ClinicalTrials.gov Identifier: NCT06440850

  20. (fwelo2024impactofamerican pages 2-4): Pierre Fwelo, Natalia I. Heredia, Ruosha Li, Ayrton Bangolo, Vignesh K. Nagesh, Simcha Weissman, and Xianglin L. Du. Impact of american thyroid association’s revised cancer management guidelines on thyroid cancer incidence trends: a retrospective cohort study, 2000–2020. Journal of Clinical Medicine, 14:28, Dec 2024. URL: https://doi.org/10.3390/jcm14010028, doi:10.3390/jcm14010028. This article has 2 citations.

  21. (fagin2023pathogenesisofcancers pages 24-25): James A. Fagin, Gnana P. Krishnamoorthy, and Iñigo Landa. Pathogenesis of cancers derived from thyroid follicular cells. Nature Reviews Cancer, 23:631-650, Jul 2023. URL: https://doi.org/10.1038/s41568-023-00598-y, doi:10.1038/s41568-023-00598-y. This article has 77 citations and is from a domain leading peer-reviewed journal.

  22. (yu2023molecularbasisand pages 5-6): Qiuxiao Yu, Xuwen Zhang, Li Li, Chi-zhi Zhang, Jian Huang, and Wenting Huang. Molecular basis and targeted therapies for radioiodine refractory thyroid cancer. Asia‐Pacific Journal of Clinical Oncology, 19:279-289, Aug 2023. URL: https://doi.org/10.1111/ajco.13836, doi:10.1111/ajco.13836. This article has 16 citations.